Psoriasis is a chronic inflammatory disease with a strong genetic component that can be
triggered by environmental factors. Disease pathogenesis is mainly driven by type 1 and …

A lack of regulatory T (TReg) cells that express CD4, CD25 and forkhead box P3 (FOXP3)
results in severe autoimmunity in both mice and humans. Since the discovery of TReg cells …

Psoriasis is a common, chronic immune-mediated systemic disease that had no effective
and durable treatment. Mesenchymal stem cells (MSCs) have immunomodulatory …

Psoriasis is considered an immune chronic disease in which T cells are accepted as
important. Nowadays, it is believed that psoriasis is most likely a T helper (Th) 1/Th17 …

Psoriasis vulgaris (PV) is a chronic inflammatory and T cell-mediated autoimmune skin
disease. An immune dysfunction that is manifested by abnormally activated T cells and …

Psoriasis is a chronic, relapsing, autoimmune disorder of the skin affecting 2–3% of general
population. Approximately 30% of psoriasis patients are also affected with the psoriatic …

The S100A8/A9 heterocomplex is an abundant damage-associated molecular pattern and
mainly expressed by monocytes, inflammatory activated keratinocytes and neutrophilic …

Psoriasis is a recurring inflammatory skin condition characterized by scaly, red patches on
the skin. It affects approximately 3% of the US population and is associated with histological …

Background: Psoriasis is sustained by pro-inflammatory CD4+ T helper cells mainly
belonging to the Th1, Th17 and Th22 lineage. Objective: To identify whether treatment with …

Background Immune therapies may act in inflammatory bowel diseases (IBD) by modulating
regulatory T cells (Tregs). Therefore, we investigated the effect of infliximab (IFX) therapy on …